EDT Absci (ABSI) files to sell 5.71M shares of common stock for holdersDon't Miss Our End of Quarter Offers: Discover the latest stocks ...

Absci Corporation stock has dropped since January, driven by weak earnings and broader biotech sector pressures. Learn more ...

Absci reported quarterly losses of 25 cents per share which missed the analyst consensus estimate of 23 cents per share. This is unchanged from the same period last year. The company reported ...

In the world of upstart pharmaceuticals and healthcare companies, timing is everything. These firms often struggle for an ...

The company also announced a collaboration with chipmaker AMD to power its advanced de novo AI antibody design models, as well as AI biotechnology company Owkin to co-develop therapeutic candidates ...

Pre-earnings options volume in AbSci Corp is normal with calls leading puts 8:3. Implied volatility suggests the market is anticipating a move near 16.5%, or 51c, after results ar ...

VANCOUVER, Wash. and NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced that on March 3, 2025 ...

Absci (NASDAQ:ABSI – Get Free Report)‘s stock had its “buy” rating reissued by research analysts at Guggenheim in a research ...

Thank you for standing by. Welcome to Absci's fourth-quarter and full-year 2024 business update and financial operating results conference call. (Operator Instructions) As a reminder, today's ...

Ratings for Absci (NASDAQ:ABSI) were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table encapsulates their recent ratings ...

Achieved 2024 outlook for drug creation partnerships through collaborations with Owkin, Twist Bioscience, Invetx, and Memorial Sloan Kettering Cancer Center Absci continues to focus its ...